In vivo efficacy studies were performed in a healthy murinemodel, avoiding various variables associated with diabetes mouse models.According to experimental results, the GCG micelle was able to reversedeep hypoglycemic conditions in less than 25 min after injection,indicating that the glucagon formulation could be employed as an emergencytreatment for hypoglycemia. This evidence concerns the gene GCG and diabetes mellitus.